anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dominant optic atrophy (DOA) is one of the most prevalent forms of hereditary optic neuropathies and is mainly caused by heterozygous variants in OPA1, encoding a mitochondrial dynamin-related large GTPase. The clinical spectrum of DOA has been extended to a wide variety of syndromic presentations, called DOAplus, including deafness as the main secondary symptom associated to vision impairment. To date, the pathophysiological mechanisms underlying the deafness in DOA remain unknown. To gain insights into the process leading to hearing impairment, we have analyzed the Opa1delTTAG mouse model that recapitulates the DOAplus syndrome through complementary approaches combining morpho-physiology, biochemistry, and cellular and molecular biology. We found that Opa1delTTAG mutation leads an adult-onset progressive auditory neuropathy in mice, as attested by the auditory brainstem response threshold shift over time. However, the mutant mice harbored larger otoacoustic emissions in comparison to wild-type littermates, whereas the endocochlear potential, which is a proxy for the functional state of the stria vascularis, was comparable between both genotypes. Ultrastructural examination of the mutant mice revealed a selective loss of sensory inner hair cells, together with a progressive degeneration of the axons and myelin sheaths of the afferent terminals of the spiral ganglion neurons, supporting an auditory neuropathy spectrum disorder (ANSD). Molecular assessment of cochlea demonstrated a reduction of Opa1 mRNA level by greater than 40%, supporting haploinsufficiency as the disease mechanism. In addition, we evidenced an early increase in Sirtuin 3 level and in Beclin1 activity, and subsequently an age-related mtDNA depletion, increased oxidative stress, mitophagy as well as an impaired autophagic flux. Together, these results support a novel role for OPA1 in the maintenance of inner hair cells and auditory neural structures, addressing new challenges for the exploration and treatment of OPA1-linked ANSD in patients.
Participants in the control group will have access to online the sleep diary and sleep education material for 12 weeks, without the CBTi intervention by the Sleepio™ app (Big Health Ltd., London, UK). They will start the digital cognitive behavioral therapy for insomnia (dCBTi) intervention 12 weeks after the initial enrollment.
The proposed trial is a pilot study that will accrue 30 patients with inoperable stage IIIA/B NSCLC harboring either an EGFR mutation (n=20) or an ALK rearrangement (n=10). Patients with EGFR+ tumors will be treated with erlotinib 150 mg orally QD; patients with ALK+ tumors will be treated with crizotinib 250 mg orally BID. Treatment consists of six weeks of concurrent PART plus erlotinib or crizotinib, followed by erlotinib or crizotinib for a total of 1 year. All patients will be treated with response-driven PART with dose intensified to the active (FDG-avid) region based on a mid-treatment FDG-PET/CT scan while maintaining dose limits for organs-at-risk. The primary endpoints will be PFS and OS. Primary analyses will be performed separately for ALK+ and EGFR+ patients. The secondary endpoint of treatment-related toxicity will focus on pneumonitis and esophagitis with a strict stopping rule in place.

Current standard therapy affords suboptimal outcomes for patients with locally advanced NSCLC due to both locoregional and distant recurrences. Since targeted therapy is more effective than chemotherapy in patients with relevant driver mutations, the best way to significantly improve outcomes in this subgroup of patients is to optimize systemic therapy with targeted agents while improving local control with PET-adapted, high-dose RT.
Although hemivertebra resection technique can obtain satisfactory clinical outcome, it has its disadvantages. Because of the presence of vertebral arteries, the procedure of cervical hemivertebra resection is not only difficult and risky, but also time and labor consuming. The operation is a great challenge to the skill, physical strength and energy of the surgical team. Meanwhile, hemivertebra resection and compression on convex side may lead to iatrogenic foraminal stenosis and increase the incidence of nerve root palsy at the corresponding segment after surgery. The shortening of the convex side may further aggravate the patient's existing short neck deformity, which is not conducive to the recovery of patient's appearance. Therefore, our department pioneer a new surgical technique to avoid hemivertebra resection in 2015, which is distraction and lateral opening on concave side. This technique extends the concave side through intervertebral space where the concave apex locates or adjacent intervertebral space to achieve the purpose of scoliosis correction. The avoidance of hemivertebra resection significantly reduces the difficulty and risk of the surgery. This procedure tries to make up for the patient's congenital anatomical deficiency and lengthen the concave side. Although there is no need to expose vertebral artery, preoperative CTA(computed tomography angiography) should be performed routinely to determine whether there is abnormality in vertebral artery and whether it will interfere with the distraction on concave side and the placement of prosthesis.
PURPOSE:To purify HBs antigen, by subjecting a raw material of HBs antigen to adsorption chromatography using a silicic acid. CONSTITUTION:A raw material of HBs antigen (crude extract of HBs antigen obtained by crushing a recombinant cell by ultrasonic crushing, etc.) obtained from a culture of a recombinant provided with HBs antigen preparation ability, transformed by recombinant DNA method is subjected to adsorption chromatography using a silicic acid, most of lipids, impure proteins, etc. derived from the culture cell are removed, and a fraction containing HBs antigen free from protease active substance is obtained. It is subjected to middle purification operation by gel filtration, and subjected to affinity chromatography with hydroxyapatite, to obtain high-purity HBs antigen. EFFECT:Purified standard HBs antigen capable of supplying stably a large amount of safe and effective hepatitis B vaccine can be obtained in high yield of >=40% from the raw material solution.
PURPOSE:To obtain a Chinese herb extract having excellent disintegrability, by contacting an extracted liquid of Chinese herb drug or its concentrated liquid with an immobilized amylase, drying the reaction product and mixing the obtained powder optionally with an excipient. CONSTITUTION:A Chinese herb drug including crude drug is extracted preferably with water at 90-100 deg.C, concentrated at 30-50 deg.C under reduced pressure, and the obtained extract liquid or its concentrate is made to contact and react with an immobilized amylase. The immobilized amylase is alpha-amylase, beta-amylase, etc., and can be produced by the conventional enzyme-immibilization method, however, a commercially available immobilized alpha-amylase (e.g. A-5386, product of Sigma Corp.) can be used for the purpose. The contact reaction can be carried out by adding the immobilized amylase directly to the extracted liquid or concentrated liquid at 6-8pH and 30-40 deg.C. The reaction liquid is dried to obtain Chinese herb extract powder, which is optionally mixed with an excipient such as starch, sugar, etc., to form Chinese herb extract drugs having various forms.
Pearl polymers containing inclusions of air and liquid are treated with solvents so as to remove at least partially the lower molecular components and deleterious inclusions to provide moulding powders of which the individual grains have a homogeneous molecular structure and corroded surfaces, yielding products of greater mechanical strength.  Polymethyl methacrylate is specified with toluene and a mixture of trichloroethylene and ethanol as solvents.  After treatment, which may be at elevated temperature and pressure, the pearls are washed, e.g. with methanol or ethanol, and dried. Mixtures of solvents including one having a swelling action on the higher molecular components and a good solvent action on the low molecular components are advantageously employed, and aqueous or non-aqueous dispersions may be used.  The polymer, alone, or mixed with monomeric methyl methacrylate, may be moulded to form articles such as dental protheses or worked in other forms.  Specifications 426,744, 518,555, 548,242, 573,805 and 593,097 are referred to.
The control group will participate in the 12-week beef dietary intervention. Participants will be provided with 5 portions of ready-to-eat beef in frozen packages per week. Each portion of beef provided to this group will weigh 1 ounces.
Midazolam injection is a potent sedative agent that requires slow administration and individualization of dosage. Clinical experience has shown midazolam hydrochloride to be 3 to 4 times as potent per mg as diazepam. BECAUSE SERIOUS AND LIFE-THREATENING CARDIORESPIRATORY ADVERSE EVENTS HAVE BEEN REPORTED, PROVISION FOR MONITORING, DETECTION AND CORRECTION OF THESE REACTIONS MUST BE MADE FOR EVERY PATIENT TO WHOM MIDAZOLAM INJECTION IS ADMINISTERED, REGARDLESS OF AGE OR HEALTH STATUS. Excessive single doses or rapid intravenous administration may result in respiratory depression, airway obstruction and/or arrest. The potential for these latter effects is increased in debilitated patients, those receiving concomitant medications capable of depressing the CNS, and patients without an endotracheal tube but undergoing a procedure involving the upper airway such as endoscopy or dental (see Boxed WARNING and WARNINGS). 

Reactions such as agitation, involuntary movements, hyperactivity and combativeness have been reported in adult and pediatric patients. Should such reactions occur, caution should be exercised before continuing administration of midazolam hydrochloride (see WARNINGS). 

Midazolam injection should only be administered IM or IV (see WARNINGS). 

Care should be taken to avoid intra-arterial injection or extravasation (see WARNINGS). 

Midazolam injection may be mixed in the same syringe with the following frequently used premedications: morphine sulfate, meperidine, atropine sulfate or scopolamine. Midazolam, at a concentration of 0.5 mg/mL, is compatible with 5% dextrose in water and 0.9% sodium chloride for up to 24 hours and with lactated Ringer's solution for up to 4 hours. The 1 mg/mL formulation of midazolam may be diluted with 0.9% sodium chloride or 5% dextrose in water.
<P>PROBLEM TO BE SOLVED: To provide a local bone growth promoter, and to provide a kit for promoting local bone growth.  <P>SOLUTION: The local bone growth promoter comprises, as active ingredient, a cytotrophic factor, being intended for stretching one's legs. This promoter is characterized in being locally administered(preferably continuously) to the bone. This promoter is to be continuously locally injected directly into an epiphysis. This promoter is a medicament for stretching human legs to treat diseases with different leg lengths selected from the group consisting of limb length deficiency and scoliosis. The limb length deficiency is such as to be seen in the childhood. This promoter is also a medicament for stretching one's legs in the cosmetic surgery. The kit for promoting local bone growth is also provided, being intended for administering a relevant injection into an epiphysis, and comprising an injection needle for directly injecting the medicament into an epiphysis, fixing the needle tip onto the osteoepiphysis and a pump for sustainedly injecting the medicament into the epiphysis, wherein the injection needle is in the form of fixing the needle tip onto an epiphysis. In this kit, the pump is to be used in vitro or in vivo, and the cytotrophic factor is a bone growth factor selected from the group consisting of growth hormone, somatomedin C and fibroblast growth factor.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The evaluation of new therapies in adults with Attention Deficit/Hyperactivity Disorder (ADHD) may be clinically useful. Rhodiola rosea is an herbal medicine used for centuries in various medical conditions. Many randomized controlled trials have evaluated its usefulness in stress and fatigue. There were benefits in attention in some of these studies. Mild side effects and beneficial antioxidant properties make reasonable an assessment of its potential benefits in adults with ADHD. To our knowledge, Rhodiola rosea has never been studied in adults with ADHD.
Thiotepa for injection is a cytotoxic drug. Follow applicable special handling and disposal procedures1.

Reconstitution

Reconstitute thiotepa for injection 15 mg with 1.5 mL of sterile water for injection. Using a syringe fitted with a needle, aseptically withdraw 1.5 mL of sterile water for injection. Inject the content of the syringe into the vial through the rubber stopper. Remove the syringe and needle, and mix manually by repeated inversions.

Reconstitute thiotepa for injection 100 mg with 10 mL of sterile water for injection. Using a syringe fitted with a needle, aseptically withdraw 10 mL of sterile water for injection. Inject the content of the syringe into the vial through the rubber stopper. Remove the syringe and needle, and mix manually by repeated inversions.

The reconstituted solution is hypotonic and must be diluted in saline prior to administration. Reconstituted solutions, free of visible particulate matter, may occasionally show opalescence; such solutions can still be used for further dilution. If not used immediately after reconstitution, the product is stable for 8 hours when stored at 2° to 8°C (36° to 46°F).

Dilution in the Infusion Bag

Prior to administration, dilute the reconstituted solution further with an appropriate volume of sodium chloride 0.9% solution for injection to obtain a final thiotepa for injection concentration between 0.5 and 1 mg per mL. Dilute thiotepa for injection as recommended in Table 2.

###  Table 2: Dilution of Thiotepa in the Infusion Bag

After dilution the product is stable for 24 hours when stored at 2° to 8°C (36° to 46°F) and for 4 hours when stored at 25°C (77°F). From a microbiological point of view, the product should be used immediately. Discard unused portion.

Inspect the diluted solution visually for particulate matter and discoloration prior to administration. Use thiotepa for injection diluted solutions only if free of visible particulate matter. Filter using a 0.2 micron filter prior to administration. Filtering does not alter solution potency.
Angelman Syndrome (AS) is a genetic disorder occurring in approximately one in every 15,000 births. It is characterized by severe mental retardation, seizures, difficulty speaking and ataxia. The gene responsible for AS was discovered to be UBE3A and encodes for E6-AP, an ubiquitin ligase. A unique feature of this gene is that it undergoes maternal imprinting in a neuron-specific manner. In the majority of AS cases, there is a mutation or deletion in the maternally inherited UBE3A gene, although other cases are the result of uniparental disomy or mismethylation of the maternal gene. While most human disorders characterized by severe mental retardation involve abnormalities in brain structure, no gross anatomical changes are associated with AS. We have generated a Ube3a protein with additional sequences that should allow the secretion from cells and uptake by neighboring neuronal cells. This would confer a functional E6-AP protein into the neurons and rescue disease pathology.
The head of the infant was positioned in the midline, slightly extended, with the chin up. The head was stabilized with the right hand by turning on the light of the laryngoscope. The blade of the laryngoscope was inserted by sliding the blade over the tongue until the tip of the blade rested on the Vallecula. The blade of the laryngoscope was slid up to open the mouth even more. The other assistant gently dipped it into the suprasternal notch. The concave edge of the tube was held with the right hand, and it was advanced approximately 2 cm, passing it between the vocal cords when the vocal cords and trachea were seen.
Monitor vital signs and observe the patient for signs and symptoms of opioid withdrawal. These may include, but are not limited to: nausea, vomiting, dysphoria, yawning, sweating, tearing, rhinorrhea, stuffy nose, craving for opioids, poor appetite, abdominal cramps, sense of fear, skin erythema, disrupted sleep patterns, fidgeting, uneasiness, poor ability to focus, mental lapses, muscle aches or cramps, pupillary dilation, piloerection, fever, changes in blood pressure, pulse or temperature, anxiety, depression, irritability, backache, bone or joint pains, tremors, sensations of skin crawling or fasciculations. If signs or symptoms of withdrawal appear, the test is positive and no additional naloxone should be administered.

Warning: If the test is positive, do NOT initiate naltrexone hydrochloride therapy. Repeat the challenge in 24 hours. If the test is negative, naltrexone hydrochloride therapy may be started if no other contraindications are present. If there is any doubt about the result of the test, hold naltrexone hydrochloride and repeat the challenge in 24 hours.
A cpd. (I) having modulatory activity on the POMC-dependent metabolic pathway (POMC = pro-opio-melano-cortin) is used to prepare a medicament for treatment and prevention of retroviral infections. Pref. (I) is a benzofuran or benzopyran deriv. which modulates the immunomodulatory and antiinflammatory activity of alpha-MSH and acts as a photosensitiser or pigmentation agent, esp. and alkylated, hydroxylated or alkoxylated psoralen or isopsoralen deriv. esp. 5-methoxypsoralen (Ia). The medicament is formulated for oral admin. and also contains cytoprotective agents, esp. vitamin A and beta-carotene. The medicament may also contain an antiviral agent. USE/ADVANTAGE - The medicament may be used to treat AIDS patients, HIV-positive subjects, and subjects who are HIV-negative but at risk. The treatment may stabilise or increase T4 cell counts and/or normalise cortisol/beta-endorphin and ACTH/beta-endorphin ratios (see also FR 9007503).
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: invention relates to preparing of curative-prophylactic agent showing the general tonic and restorative effects. Invention proposes two variants of agents involving green tea dry extract and special supplements. Invention proposes also a method of preparing this agent and a method of preparing green tea dry extract. This agent can be used widely both in home conditions and in station health, it enhances tonus, working ability and does not adverse effects. EFFECT: high effectiveness of agent, valuable properties. 12 cl
BACKGROUND AND OBJECTIVES: Nonfluent variant primary progressive aphasia (nfvPPA) and primary progressive apraxia of speech (PPAOS) can be precursors to corticobasal syndrome (CBS). Details on their progression remain unclear. We aimed to examine the clinical and neuroimaging evolution of nfvPPA and PPAOS into CBS.
METHODS: We conducted a retrospective longitudinal study in 140 nfvPPA or PPAOS patients and applied the consensus criteria for possible and probable CBS for every visit, evaluating limb rigidity, akinesia, limb dystonia, myoclonus, ideomotor apraxia, alien limb phenomenon, and nonverbal oral apraxia (NVOA). Given the association of NVOA with AOS, we also modified the CBS criteria by excluding NVOA and assigned every patient to either a progressors or non-progressors group. We evaluated the frequency of every CBS feature by year from disease onset, and assessed gray and white matter volume loss using SPM12.
RESULTS: Asymmetric akinesia, NVOA, and limb apraxia were the most common CBS features that developed; while limb dystonia, myoclonus, and alien limb were rare. Eighty-two patients progressed to possible CBS; only four to probable CBS. nfvPPA and PPAOS had a similar proportion of progressors, although nfvPPA progressed to CBS earlier (p-value = 0.046), driven by an early appearance of limb apraxia (p-value = 0.0041). The non-progressors and progressors both showed premotor/motor cortex involvement at baseline, with spread into prefrontal cortex over time.
DISCUSSION: An important proportion of patients with nfvPPA and PPAOS progress to possible CBS, while they rarely develop features of probable CBS even after long follow-up.
BACKGROUND: The use of double gloving has become a standard practice for joint replacement surgeons. However, since there are limited data on how gloves are contaminated during both primary and revision arthroplasty, no precise protocol exists to direct surgeons on when, or if, to change their gloves. The goals of this preliminary study were to evaluate the contamination of gloves during total joint arthroplasties (TJAs).
METHODS: We included 25 infected cases and 10 primaries, which were performed at the same institution using the same surgical protocol from 3 fellowship trained surgeons. Samples were taken every 20 minutes from the start of the surgery until the joint was irrigated. Procedural steps were noted. To evaluate cross-contamination during infected cases, we sampled gloves using blood agar plates. In primary cases, culture swabs of anterior chamfer cuts and sterile instruments on the back table were used as negative controls. Next-generation sequencing (NGS) was used as an adjunct to identify low virulence bacteria.
RESULTS: In the primary cases, all samples were found culture negative but 3 (8.1%) of the 37 samples were found to have a low, unidentifiable bacterial mass via NGS testing. In the infected cases, 41 (59.4%) of the 69 samples yielded positive microbial results. The positivity rate was higher in the samples collected after the arthrotomy was performed (70%) compared to samples collected before the arthrotomy was performed (40%), and the surgeon was only dissecting superficial layers (P = .502).
CONCLUSION: Gloves seem to be a common source of cross-contamination in the intraoperative field during revision TJA. Due to the higher percent of positive samples following the opening of the joint, we hypothesize that the arthrotomy allows for the spread of bacteria across the operative site. While further investigation is necessary to formulate a precise protocol for the changing of gloves during TJA, it may be beneficial to perform a thorough irrigation of the joint and change of the gloves immediately following arthrotomy.
PURPOSE: A composition containing 3-methyl-1,2-cyclopentanedione is provide to suppress differentiation of adipocyte precursor cells to adipocytes and to treat obesity with safety. CONSTITUTION: A composition for suppressing and treating obesity contains 3-methyl-1,2-cyclopentanedione of chemical formula 1 as an active ingredient. The composition is a food or pharmaceutical composition. A beverage, food, or food additive contains 3-methyl-1,2-cyclopentanedione as an active ingredient. The adipocyte precursor cell is 3T3-L1. The compound of chemical formula 1 is derived from coffee.
For patients presenting with synchronous disease who require two separate surgical sessions (i.e. separate liver and primary cancer surgery), and who do receive pre-surgical chemotherapy, three \[18F\]-ALF-FAPI-74 PET/CTs will be performed: one before chemotherapy and one before each surgical session.
Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by [3-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.